0.47
price up icon0.99%   0.0046
pre-market  Pre-market:  .47  
loading
Azitra Inc stock is traded at $0.47, with a volume of 52,470. It is up +0.99% in the last 24 hours and down -22.95% over the past month. Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
See More
Previous Close:
$0.4654
Open:
$0.4551
24h Volume:
52,470
Relative Volume:
0.11
Market Cap:
$3.55M
Revenue:
$686.00K
Net Income/Loss:
$-11.76M
P/E Ratio:
-0.1523
EPS:
-3.0856
Net Cash Flow:
$-9.40M
1W Performance:
-4.04%
1M Performance:
-22.95%
6M Performance:
+141.27%
1Y Performance:
-68.67%
1-Day Range:
Value
$0.452
$0.4763
1-Week Range:
Value
$0.4264
$0.486
52-Week Range:
Value
$0.0922
$12.00

Azitra Inc Stock (AZTR) Company Profile

Name
Name
Azitra Inc
Name
Phone
203 646 6446
Name
Address
21 Business Park Drive, Branford
Name
Employee
10
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
AZTR's Discussions on Twitter

Compare AZTR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
AZTR 0.47 3.55M 686.00K -11.76M -9.40M -3.0856
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Azitra Inc Stock (AZTR) Latest News

pulisher
Nov 15, 2024

AZTR: Planning 2nd Site for ATR-12 Trial - MSN

Nov 15, 2024
pulisher
Nov 14, 2024

Azitra stock plunges to 52-week low at $0.46 amid steep decline - Investing.com Australia

Nov 14, 2024
pulisher
Nov 14, 2024

500: Something went wrong - Investing.com Canada

Nov 14, 2024
pulisher
Nov 14, 2024

Azitra (NYSEAMERICAN:AZTR) Shares Down 3.9% – Here’s Why - Defense World

Nov 14, 2024
pulisher
Nov 12, 2024

Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates - PR Newswire

Nov 12, 2024
pulisher
Oct 29, 2024

Azitra to Present at BIO-Europe 2024 - BioSpace

Oct 29, 2024
pulisher
Oct 14, 2024

Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit - Marketscreener.com

Oct 14, 2024
pulisher
Oct 13, 2024

Azitra Joins 2024 Maxim Healthcare Virtual Summit - FinancialNews.co.uk

Oct 13, 2024
pulisher
Oct 13, 2024

Netherton Syndrome Treatment Industry is Expected to Reach $8 Billion by 2034 -Lifemax Laboratories, Azitra, Inc, Sixera – IndiaPolitics.com - IndiaPolitics.com

Oct 13, 2024
pulisher
Oct 08, 2024

Azitra stock plunges to 52-week low, hits $0.49 By Investing.com - Investing.com South Africa

Oct 08, 2024
pulisher
Oct 08, 2024

Azitra stock plunges to 52-week low, hits $0.49 - Investing.com

Oct 08, 2024
pulisher
Sep 30, 2024

Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga

Sep 30, 2024
pulisher
Sep 25, 2024

Azitra to present EGFR inhibitor toxicity treatment data By Investing.com - Investing.com Australia

Sep 25, 2024
pulisher
Sep 24, 2024

Azitra to present EGFR inhibitor toxicity treatment data - Investing.com India

Sep 24, 2024
pulisher
Sep 24, 2024

AZTRAzitra Inc Latest Stock News & Market Updates - StockTitan

Sep 24, 2024
pulisher
Sep 24, 2024

Mexico's inflation undershoots forecasts ahead of rate decision - Investing.com

Sep 24, 2024
pulisher
Sep 24, 2024

Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress - Business Wire

Sep 24, 2024
pulisher
Sep 18, 2024

AZTR’s Market Fluctuations: Is Now the Right Time to Invest? - The InvestChronicle

Sep 18, 2024
pulisher
Sep 18, 2024

FDA fast tracks Azitra's new dermatology treatment - Investing.com

Sep 18, 2024
pulisher
Sep 18, 2024

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors - StockTitan

Sep 18, 2024
pulisher
Sep 11, 2024

Taking a Closer Look At Azitra Inc (AZTR) Following Its Recent Trade - Knox Daily

Sep 11, 2024
pulisher
Sep 06, 2024

Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com

Sep 06, 2024
pulisher
Sep 04, 2024

Azitra (NYSEAMERICAN:AZTR) Stock Price Down 7.8% - Defense World

Sep 04, 2024
pulisher
Sep 03, 2024

Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Update - Defense World

Sep 03, 2024
pulisher
Sep 02, 2024

Azitra Inc’s latest rating changes from various analysts - Knox Daily

Sep 02, 2024
pulisher
Sep 02, 2024

A significant driver of top-line growth: Azitra Inc (AZTR) - SETE News

Sep 02, 2024
pulisher
Sep 02, 2024

Financial Metrics Exploration: Understanding Azitra Inc (AZTR) Through Ratios - The Dwinnex

Sep 02, 2024
pulisher
Sep 02, 2024

Do investors need to be concerned about Azitra Inc (AZTR)? - US Post News

Sep 02, 2024
pulisher
Aug 29, 2024

Azitra doses first subject in Phase Ib Netherton syndrome treatment trial - Yahoo Finance

Aug 29, 2024
pulisher
Aug 28, 2024

Azitra begins phase 1b trial for Netherton syndrome treatment - Investing.com

Aug 28, 2024
pulisher
Aug 28, 2024

Views of Wall Street’s Leading Experts on Azitra Inc - SETE News

Aug 28, 2024
pulisher
Aug 28, 2024

Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome - Marketscreener.com

Aug 28, 2024
pulisher
Aug 26, 2024

Trading Day Triumph: Azitra Inc (AZTR) Ends at 0.71, a -5.08 Surge/Plunge - The Dwinnex

Aug 26, 2024
pulisher
Aug 23, 2024

Azitra Inc [AZTR] stock for 10,034 USD was bought by Staskey Norm - Knox Daily

Aug 23, 2024
pulisher
Aug 22, 2024

FDA clears Azitra's Phase 1/2 trial for skin rash treatment - Investing.com

Aug 22, 2024
pulisher
Aug 22, 2024

Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors - Marketscreener.com

Aug 22, 2024
pulisher
Aug 22, 2024

A Look at Azitra Inc (AZTR) Shares in the Recent Past Indicates Growth - SETE News

Aug 22, 2024
pulisher
Aug 21, 2024

Investing in Azitra Inc (AZTR) Is Getting More Attractive - Knox Daily

Aug 21, 2024
pulisher
Aug 21, 2024

Azitra Inc Inc. (AZTR) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle

Aug 21, 2024
pulisher
Aug 21, 2024

Understanding AZTR stock ratios for better investment decisions - US Post News

Aug 21, 2024
pulisher
Aug 21, 2024

Ratio Revelations: Azitra Inc (AZTR)’s Financial Metrics in the Spotlight - The Dwinnex

Aug 21, 2024
pulisher
Aug 21, 2024

Azitra screens first subject in Phase Ib trial of ATR-12 for Netherton syndrome - Clinical Trials Arena

Aug 21, 2024
pulisher
Aug 20, 2024

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome - Marketscreener.com

Aug 20, 2024
pulisher
Aug 20, 2024

Azitra, Inc. Announces First Patient Screened and Scheduled to Enroll in Phase 1B Trial of ATR-12 for Netherton Syndrome - Marketscreener.com

Aug 20, 2024

Azitra Inc Stock (AZTR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):